Allulose
A rare sugar (D-psicose) that tastes like sugar with ~70% of the sweetness, but contributes ~0.4 kcal/g and has minimal impact on blood sugar.
Should I eat Allulose?
Allulose is a very low‑calorie, sugar‑like sweetener that has little effect on blood sugar. For most people it is a useful sugar reducer when portioned sensibly, though large doses can upset digestion and EU authorization is pending.
Summary
Allulose is a rare sugar made by enzymatically converting fructose, then purifying the product; the enzyme is not present in the final sweetener. Human studies show minimal glycemic impact and smaller post‑meal glucose spikes when it replaces part of sucrose, supporting its use in lower‑sugar foods. The US recognizes 0.4 kcal/g for labeling and excludes allulose from Added and Total Sugars, while Australia/New Zealand approve it with intake advisories. The main practical downside is GI intolerance at higher doses. EFSA (2025) could not establish safety, so it is not authorized in the EU at this time.
Key Research Benefits
Key Research Risks
Overview
What is it?
Why is it used?
Origin
Allulose (D-psicose) was identified in the 1940s in trace amounts in foods like wheat, figs and raisins. Practical production took off after Japanese researchers in the 1990s discovered enzymes (D-psicose/D-tagatose 3-epimerases) that flip the C-3 position of fructose to form allulose, enabling large-scale manufacture from fructose syrups made from corn or beet sugar. Since then, it has been studied as a low-energy ‘rare sugar’ with sugar-like functionality.
Process: Epimerize fructose, then refine & crystallize
Steps
Chemicals
Research & Safety
Research Summary
Digestive Effects
Allulose can draw water into the gut (an osmotic effect), which is why high doses may cause gas, cramping, or loose stools. Human data suggest most adults tolerate up to about 0.4 g/kg in a single dose and about 0.9 g/kg spread across a day. Sensitive individuals, including people with IBS and children, may experience symptoms at lower amounts, so starting low and increasing slowly is prudent. If you notice GI symptoms, reduce the serving size or space out intake over the day.
Limit Consumption
People with type 2 diabetes may see modest reductions in post‑meal glucose when using allulose in place of some sugar; monitor your readings when making changes to your diet. Children and those with IBS or sensitive digestion are more likely to experience GI symptoms at lower doses, so conservative servings are advised. There are limited data in infants; it is not specifically recommended for infant foods, and high doses should be avoided. Toxicology assessments have not identified genotoxic or reproductive/developmental concerns at intended uses, but EFSA did not establish overall safety for EU authorization, reflecting remaining uncertainties.
Fact Sheet
Regulatory Status
ESG & Sustainability
Allergens and Diet
Natural Alternatives
Honey
Date paste
Maple syrup
Citations
Guidance on the Declaration of Allulose and Calories from Allulose on Nutrition and Supplement Facts Labels
2020-10-16FDA CFSAN • FDA
GRAS Notice GRN 1057 Agency Response Letter (D-psicose)
2024-01-25FDA • FDA
Safety of D-allulose as a novel food
2025-06-05EFSA Panel on Nutrition • EFSA Journal
Approval report – Application A1247 D-allulose as a novel food
2024-08-19FSANZ • FSANZ
Comparison of postprandial glycemic and insulinemic responses with allulose + sucrose vs sucrose alone
2023-07-01Au-Yeung F, et al. • Food Chemistry: X
Impact of allulose on blood glucose in type 2 diabetes
2024-05-01Ayesh H, et al. • Diabetes Research and Clinical Practice
Gastrointestinal Tolerance of D-Allulose in Healthy and Young Adults
2018-12-20Han Y, et al. • Nutrients
Food enzyme d-psicose 3-epimerase (E. coli K-12 W3110) used to produce D-allulose
2021-04-30EFSA CEP Panel • EFSA Journal
GRAS Notice (GRN) No. 693 – D-psicose (background referencing GRN 400, 498)
2017-02-02FDA • FDA
Allulose for the attenuation of postprandial blood glucose
2023-03-28Yuma T, et al. • EFSA/PMC